![](https://cdn.sanity.io/images/0vv8moc6/oncnurse/5cd3582b78724e9781c830be05778594f03d0004-1088x599.png?fit=crop&auto=format)
Real-World Data Show That Most Patients With HER2-Positive mBC Discontinued Second-Line Treatment
Most patients with HER2-positive metastatic breast cancer discontinued second-line treatment in US community practices, which may underscore the need for timely second-line treatment, according to findings from a real-world study published in the …